New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
12:46 EDTBAYRY, ONXXOnyx Pharmaceuticals expects to initiate Phase 3 carfilzomib trial in 2013
As part of the global commercialization strategy for Kyprolis, Onyx (ONXX) is exploring opportunities in countries outside of the U.S. that consider marketing authorization based on U.S. approval. Onyx expects to pursue agreements with established distributors for regulatory and commercialization activities in those markets. Last week, Onyx and Bayer (BAYRY) announced top-line results from the DECISION trial in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The study met its primary endpoint of improving progression-free survival. Full results are expected to be presented at an upcoming medical meeting. The companies anticipate that this data will form the basis for regulatory submission of Nexavar in the treatment of RAI-refractory differentiated thyroid cancer.In the first half of 2013, enrollment is expected to complete in the RESILIENCE trial, a Phase 3 study comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer.
News For ONXX;BAYRY From The Last 14 Days
Check below for free stories on ONXX;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
19:05 EDTBAYRYBayer, Onyx report publishing of positive Phase 3 trial results
Subscribe for More Information
April 21, 2014
07:21 EDTBAYRYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 17, 2014
15:05 EDTBAYRYBayer non-cystic fibrosis bronchiectasis treatment gets FDA orphan designation
According to a post on the FDA's website, Bayer's ciprofloxacin dry powder inhaler to treat non-cystic fibrosis bronchiectasis received orphan designation. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use